CompletedNCT00812058
A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression
Researchers compared RG2417 and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared RG2417 and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 35 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNovember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 180
- Sponsor
- Repligen Corporation
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00812058
- Official title
Show the full official title
A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of RG2417 (Uridine) in the Treatment of Bipolar I Depression
Get this study by email
Recruitment & locations
CompletedBirmingham · Little Rock · San Diego
33 more locations
- New Haven
- North Miami
- Orlando
- Tampa
- Atlanta
- Smyrna
- Greenwood
- Shreveport
- Baltimore
- Boston
- Rochester
- Staten Island
- Chapel Hill
- Durham
- Raleigh
- Cincinnati
- Cleveland
- Dayton
- Oklahoma City
- Portland
- Pittsburgh
- Lincoln
- Charleston
- Memphis
- Nashville
- Austin
- Dallas
- Houston
- San Antonio
- Salt Lake City
- Charlottesville
- Bellevue
- Middleton
Questions about this study
What did researchers investigate?
Researchers compared RG2417 and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Who is behind this study?
The study sponsor is Repligen Corporation.
Did this study involve medication?
Yes. The study involved medication, including RG2417 and Placebo.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
